Senores Pharmaceuticals IPO
Senores Pharmaceuticals IPO — date, price band, lot size & details 2024
Senores Pharmaceuticals listed on 30 Dec 2024 at ₹600, 53.5% above the ₹391 issue price.
Senores Pharmaceuticals is a research driven generic pharmaceutical company focused on regulated markets such as the US, Canada and the UK. Its total income was Rs 217.34 crore in FY2024.
Stock price
Senores Pharmaceuticals is listed — here is the live share price.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Timetable
Key dates from opening to listing. Today is 11 November.
- Open 20 Dec 2024
- Close 24 Dec 2024
- Allotment 26 Dec 2024
- Refund/credit 27 Dec 2024
- Listing 30 Dec 2024
Issue summary
The terms of the offer, as filed.
| IPO Dates | 20 to 24 Dec, 2024 |
|---|---|
| Price Band | ₹372 – ₹391 |
| Face Value | ₹10 |
| Lot Size | 38 Shares |
| Issue Size | ₹582.11 Cr |
| Sale Type | Fresh capital cum OFS |
| Listing On | BSE, NSE |
| Registrar | MUFG Intime India Private Limited |
| Min Investment | ₹ 14,858 |
Share of the offer set aside for each investor category, as stated in the offer document.
What will it cost me?
Bidding is in multiples of 38 shares at the ₹391 cut-off. Drag to size your application.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (min) | 1 | 38 | ₹14,858 |
| Retail (max) | 13 | 494 | ₹1,93,154 |
| S-HNI (min) | 14 | 532 | ₹2,08,012 |
| S-HNI (max) | 67 | 2,546 | ₹9,95,486 |
| B-HNI (min) | 68 | 2,584 | ₹10,10,344 |
Strengths & risks
Drawn from the offer document — the case for and against, side by side.
Strengths · 5
- 01Total income rose from Rs 14.63 crore in FY2022 to Rs 217.34 crore in FY2024.
- 02Profit after tax rose from Rs 0.99 crore in FY2022 to Rs 32.71 crore in FY2024.
- 03Profit after tax was Rs 23.94 crore in the six months to 30 September 2024.
- 04Rs 500.00 crore of the issue was fresh capital for a new plant and debt repayment.
- 05The source puts the PAT margin at 15.25%.
Risks · 5
- 01The pre-issue P/E was 39.77 at the upper band of Rs 391, based on EPS of Rs 9.83.
- 02Total borrowing rose from Rs 14.21 crore on 31 March 2022 to Rs 242.03 crore on 30 September 2024.
- 03Growth has come very fast, from total income of Rs 39.02 crore in FY2023, including through acquisitions, which needs strong integration.
- 04US and other regulated markets have strict inspections and pricing pressure, and the source puts debt to equity at 1.07.
- 05Promoters and the promoter group held 66.67% before the issue and 45.77% after it.
Three years of numbers
All figures in ₹ crore, as reported in the Senores Pharmaceuticals offer document.
| Metric | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 678.08 | 621.88 | 131.05 | 59.15 |
| Total Income | 183.35 | 217.34 | 39.02 | 14.63 |
| Profit After Tax | 23.94 | 32.71 | 8.43 | 0.99 |
| NET Worth | 319.06 | 231.71 | 45.50 | 36.59 |
| Total Borrowing | 242.03 | 248.38 | 60.76 | 14.21 |
See how this IPO compares — view listing performance of all mainboard IPOs.
Valuation & key ratios
Ratios are for the latest full financial year reported in the Senores Pharmaceuticals RHP. EPS and P/E are post-issue — the table below carries the pre-issue comparison.
Senores Pharmaceuticals IPO Valuation
How the issue prices the company before and after the fresh shares are created.
| Valuation Metric | Pre-Issue | Post-Issue |
|---|---|---|
| EPS (₹) | ₹9.83 | ₹13.86 |
| P/E Ratio (x) | 39.77 | 28.21 |
| Market Cap at Offer Price (₹ Cr) | ₹952.24 | ₹675.36 |
Pre-issue figures use the shareholding reported in the RHP; post-issue figures use the shareholding once the fresh issue has created new shares. The two differ because of that dilution and because post-issue earnings per share are often annualised, so the change can run in either direction. Market capitalisation is calculated at the ₹391 offer price. Compare the post-issue P/E against listed peers before deciding — a premium there is growth you are paying for in advance.
Where the money goes
₹457.81 Cr of the issue is earmarked to named objects.
About the company
It mainly serves regulated markets such as the US, Canada and the United Kingdom across therapy areas and dosage forms, and focuses on speciality and complex niche products.
Its promoters are Swapnil Jatinbhai Shah and Ashokkumar Vijaysinh Barot.
The IPO was Rs 582.11 crore, with Rs 500.00 crore of fresh issue and Rs 82.11 crore of offer for sale by promoters, a promoter group member and another shareholder. Fresh money was planned for a sterile injectable plant, repaying borrowings and working capital.
Interested in this IPO? Check the live subscription status or browse all upcoming mainboard IPOs.
The bankers & the filings
Who is running the book, and the documents this page is built from.
Senores Pharmaceuticals IPO Documents
Read the filings this page is built from.
Lead Manager Track Record
How the book-running lead managers on this issue have priced their past IPOs, measured on listing day.
Nuvama Wealth Management Ltd.
42 issues handledBest listing: Gandhar Oil Refinery (India) (+76.3%). Weakest: ACME Solar Holdings (-13.1%).
Ambit Capital
16 issues handledBest listing: Chemcon Speciality Chemicals (+115.0%). Weakest: Metro Brands (-12.6%).
Equirus Capital Pvt.Ltd.
34 issues handledBest listing: G R Infraprojects (+105.0%). Weakest: Metro Brands (-12.6%).
Listing gain compares the listing-day opening price with the issue price, using the IPOs on IPO Guru that this lead manager has taken to market. A strong record reflects how the banker has priced past issues — it is not a forecast for this one. See every issue they have handled on the lead managers page.
Company contact
Frequently asked
What is the GMP of Senores Pharmaceuticals?
The current Grey Market Premium is ₹270, or 69% over the issue price.
What is the Senores Pharmaceuticals IPO price band?
₹372 to ₹391, on a face value of ₹10.
When is the allotment?
The basis of allotment is 26 December 2024, with listing on 30 December 2024.
How do I check allotment status?
On the IPO Guru allotment page or on the registrar's site — MUFG Intime India Private Limited.
Every number here traces back to a filing.
IPO Guru tracks GMP, subscription and allotment for every Mainboard and SME issue. Every number on this page is sourced from the RHP, BSE & NSE.
Not investment advice. Grey market premium is an unofficial, unregulated indicator and is not a forecast.
